№ files_lp_3_process_7_021325
File format: docx Character count: 28551 File size: 318 KB
The document outlines a Phase III clinical trial investigating the effects of mepolizumab as an add-on therapy for patients with eosinophilic granulomatosis with polyangiitis (EGPA), demonstrating its efficacy in improving remission duration and reducing the need for glucocorticoid use.
Year: 2023
Region / City: Multiple international locations
Topic: Clinical trial, treatment for eosinophilic granulomatosis with polyangiitis
Document Type: Research Article
Organization / Institution: GlaxoSmithKline (GSK), National Institutes of Health (NIH), various academic institutions
Author: Michael E. Wechsler, Praveen Akuthota, David Jayne, Paneez Khoury, Amy Klion, Carol A. Langford, Peter A. Merkel, Frank Moosig, Ulrich Specks, Maria C. Cid, Raashid Luqmani, Judith Brown, Stephen Mallett, Richard Philipson, Steve W. Yancey, Jonathan Steinfeld, Peter F. Weller, Gerald J. Gleich
Target Audience: Medical professionals, researchers, healthcare providers
Period of Action: 52 weeks
Approval Date: 2023-01-01
Date of Revisions: None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report
Year: 2023
Region / City: Guiyang, Guizhou Province, China
Document Type: Case report
Journal: World Journal of Clinical Cases
Authors: Jia-Ling He, Xing-Yu Liu, Yi Zhang, Li Niu, Xin-Lin Li, Xing-Yu Xie, Yang-Ting Kang, Lan-Qing Yang, Zheng-Yang Cai, Hui Long, Guang-Fei Ye, Jun-Xin Zou
Corresponding Author: Xing-Yu Xie
Department / Institution: Department of Emergency, Affiliated Hospital of Guizhou Medical University
Keywords: Eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, Asthma, Loeffler endocarditis, Case report, ANCA
Patient Age: 20
Patient Sex: Female
Symptoms: Asthma, cough, shortness of breath, chest pain
Treatment: Methylprednisolone sodium succinate, low molecular weight heparin, mycophenolate mofetil, recombinant human brain natriuretic peptide, furosemide, antibiotics, acyclovir
Hospitalization Duration: 17 days
Follow-up Status: Stable, normal eosinophil levels, restored cardiac function, reduced cardiac mural thrombus
Submission Dates: Received May 17, 2023; Revised August 18, 2023; Accepted for publication
Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report
Year: 2023
Region / City: Guiyang, Guizhou Province, China
Document Type: Case report
Journal: World Journal of Clinical Cases
Authors: Jia-Ling He, Xing-Yu Liu, Yi Zhang, Li Niu, Xin-Lin Li, Xing-Yu Xie, Yang-Ting Kang, Lan-Qing Yang, Zheng-Yang Cai, Hui Long, Guang-Fei Ye, Jun-Xin Zou
Corresponding Author: Xing-Yu Xie
Department / Institution: Department of Emergency, Affiliated Hospital of Guizhou Medical University
Keywords: Eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, Asthma, Loeffler endocarditis, Case report, ANCA
Patient Age: 20
Patient Sex: Female
Symptoms: Asthma, cough, shortness of breath, chest pain
Treatment: Methylprednisolone sodium succinate, low molecular weight heparin, mycophenolate mofetil, recombinant human brain natriuretic peptide, furosemide, antibiotics, acyclovir
Hospitalization Duration: 17 days
Follow-up Status: Stable, normal eosinophil levels, restored cardiac function, reduced cardiac mural thrombus
Submission Dates: Received May 17, 2023; Revised August 18, 2023; Accepted for publication
MEPOLIZUMAB, Injection 100 mg in 1 mL single dose pre-filled pen, Nucala®, GlaxoSmithKline Australia Pty Ltd
Year: 2022
Region / City: Australia
Theme: Chronic rhinosinusitis with nasal polyps, Pharmacology
Document Type: Application for PBS listing
Authority / Institution: PBAC, TGA
Author: GlaxoSmithKline Australia Pty Ltd
Target Audience: Healthcare professionals, medical practitioners
Validity Period: Not specified
Approval Date: Not specified
Modification Date: Not specified
MEPOLIZUMAB Powder for injection 100 mg; Injection 100 mg in 1 mL single dose pre-filled pen, Nucala®, GlaxoSmithKline Australia Pty Ltd
Year: 2023
Region / City: Australia
Subject: Pharmaceutical submission
Document Type: Submission for PBS listing amendment
Organization: GlaxoSmithKline Australia Pty Ltd
Author: Not specified
Target Audience: Healthcare professionals, government agencies
Effective Period: Not specified
Approval Date: Not specified
Date of Amendments: Not specified
Topics: granulomatosis polyangiitis MEPOLIZUMAB